Imported visceral leishmaniasis and immunosuppression in seven Norwegian patients
Open Access
- 22 August 2019
- journal article
- research article
- Published by Springer Nature in Tropical Diseases, Travel Medicine and Vaccines
- Vol. 5 (1) , 1-7
Abstract
Visceral leishmaniasis (VL) is a protozoal disease that may be aggravated by immunosuppression. In recent years, a growing number of patients with chronic diseases use biological treatment. When such immunosuppressed patients travel to endemic areas, they are facing the risk of VL. Increased incidence of leishmaniasis is reported in endemic areas like the Mediterranean basin, an area frequently visited by Norwegian tourists. This may lead to an increased number of patients, many presenting to health personnel unfamiliar with the disease, in their home countries. We reviewed the files of seven immunosuppressed patients with VL, admitted to Oslo and Haukeland University Hospitals in Norway in the period 2009–2018. The patients were 41–83 (median 66) years of age; four had rheumatic disease all of whom used methotrexate; one had advanced HIV infection, one had inflammatory bowel disease and one had myelofibrosis. Leishmania infantum was confirmed in five patients by polymerase chain reaction (PCR) and sequencing. In the remaining two patients, a definite Leishmania species could not be identified. All patients had a history of recent recreational travel to Spain. Most patients underwent extensive diagnostic work-up before diagnosed with VL. All received treatment with liposomal amphotericin B and all were cured; albeit two after re-treatment due to relapse. Visceral leishmaniasis is a potentially life-threatening but usually treatable condition. It is endemic in Southern Europe, including popular tourist destinations such as the Mediterranean basin. It is relatively unknown to most medical practitioners in non-endemic areas and clinical vigilance is required to identify those who are infected.Keywords
This publication has 27 references indexed in Scilit:
- Leishmaniasis in immunosuppressed individualsClinical Microbiology and Infection, 2014
- Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-α antagonistsTravel Medicine and Infectious Disease, 2013
- Tumor necrosis factor alpha antagonist drugs and leishmaniasis in EuropeClinical Microbiology and Infection, 2012
- Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveatsAnnals of the Rheumatic Diseases, 2012
- The role of TNF in parasitic diseases: Still more questions than answersInternational Journal for Parasitology, 2010
- Canine Leishmaniasis in Southeastern SpainEmerging Infectious Diseases, 2009
- Holiday souvenirs from the Mediterranean: Three instructive cases of visceral leishmaniasisScandinavian Journal of Infectious Diseases, 2009
- Complexities of Assessing the Disease Burden Attributable to LeishmaniasisPLOS Neglected Tropical Diseases, 2008
- Imported leishmaniasis in Germany 2001–2004: data of the SIMPID surveillance networkEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- The Epidemic of Visceral Leishmaniasis in Western Upper Nile, Southern Sudan: Course and Impact from 1984 to 1994International Journal of Epidemiology, 1996